ROPIVACAINE HYDROCHLORIDE INJECTION, USP SOLUTION

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

ROPIVACAINE HYDROCHLORIDE

Mevcut itibaren:

FRESENIUS KABI CANADA LTD

ATC kodu:

N01BB09

INN (International Adı):

ROPIVACAINE

Doz:

10MG

Farmasötik formu:

SOLUTION

Kompozisyon:

ROPIVACAINE HYDROCHLORIDE 10MG

Uygulama yolu:

EPIDURAL

Paketteki üniteler:

15G/50G

Reçete türü:

Ethical

Terapötik alanı:

LOCAL ANESTHETICS

Ürün özeti:

Active ingredient group (AIG) number: 0133273005; AHFS:

Yetkilendirme durumu:

APPROVED

Yetkilendirme tarihi:

2015-03-30

Ürün özellikleri

_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
ROPIVACAINE HYDROCHLORIDE INJECTION, USP
2 mg / mL, 5 mg / mL, and 10 mg / mL
Local Anesthetic
FRESENIUS KABI CANADA LTD.
165 Galaxy Blvd, Suite 100
Toronto, ON M9W 0C8
Date of Revision: September 25, 2023
Submission Control No: 277021
_ _
Ropivacaine Hydrochloride Injection, USP - Product Monograph
Page 2 of 42
_ _
RECENT MAJOR LABEL CHANGES
Not Applicable
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................4
1
INDICATIONS
..................................................................................................................4
1.1
Pediatrics
....................................................................................................................4
1.2
Geriatrics
....................................................................................................................4
2
CONTRAINDICATIONS
.................................................................................................4
3
DOSAGE AND ADMINISTRATION
.............................................................................5
3.1
Dosing Considerations
...............................................................................................5
3.2
Recommended Dose and Dosage Adjustment
...........................................................6
4
OVERDOSAGE
.................................................................................................................8
5
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ..............10
6
WARNINGS AND PRECAUTIONS
.............................................................................11
6.1
Special Populations
..................................................................................................16
6.1.1
Pregnant Women
.................................................................................................16
6.1.2
Breast-feeding
......................................................................................